NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

19-N-0124

Sponsoring Institute

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Children

Special Instructions

Currently Not Provided

Keywords

Chronic Active Lesions;
Ultra-high-field (7T) MRI;
Interleukin-1 (IL-1);
White Matter;
Paramagnetic Rim

Recruitment Keyword(s)

None

Condition(s)

Multiple Sclerosis

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Drug: Anakinra

Supporting Site

National Institute of Neurological Disorders and Stroke

Background:

Multiple sclerosis (MS) is a disease of the central nervous system (CNS). People who have MS may have lesions that form on parts of the CNS, such as the brain. Some of these lesions may be inflamed for a long time. This causes MS to progress. There is no treatment for these lesions. Researchers believe that a drug that decreases inflammation can help.

Objective:

To see if a drug called anakinra can help clear inflammation in MS brain lesions.

Eligibility:

People 18 and older with MS and at least one white matter lesion.

Design:

Participants will be screened with one or more Neuroimmunology Clinic protocols.

Participants will have a medical history and physical exam. They will have blood and urine tests. They will have a lumbar puncture. For this, a needle is inserted between the bones in the back, and cerebrospinal fluid is removed. They will also have an MRI of the brain. The MRI scanner is a cylinder surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the scanner.

Participants will repeat the above procedures throughout the study.

Participants will get their first dose of anakinra at the clinic. They will administer the rest of the doses themselves, by injection under the skin.

Participants will track their daily dosage electronically or in a written drug diary.

Participants will have 4 visits while taking the drug. At each visit, sharps boxes and empty vials will be collected.

Participants will have 2 follow-up visits after completing treatment.

The study will last 28 weeks.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-Age greater than or equal to 18

-Ability to give informed consent

-If fertile, agreement to use an effective method of birth control during the study and for up to 3 months after the last dose of the study drug

-Agreement not to participate in any other interventional study while participating in this protocol

-Diagnosis of MS, either stable or clinically progressive

-Prior 7-tesla MRI scan, with high image quality in the judgment of the study neuroradiologist, demonstrating at least one white matter lesion with a paramagnetic rim (41)

EXCLUSION CRITERIA:

-Pregnancy or current breastfeeding

-Use of another investigational agent within 1 month of screening

-Active infection and or neutropenia (ANC < 1000 cells/microliter)

-History of lymphoma

-Known hypersensitivity to administration of anakinra

-Previous treatment with anakinra and/or TNF-receptor inhibitor

-History of asthma

-QuantiFERON-TB gold positive

-Prior treatment with anti-CD20 agent (ocrelizumab, rituximab)

-Prior treatment with anti-CD52 agent (alemtuzumab)

-History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial or interfere with participation for the full duration of the trial; or not in the best interest of the subject to participate, in the opinion of the treating investigator

-Renal dysfunction, as defined by Clinical Center guidelines for administration of gadolinium

-Liver dysfunction, as indicated by baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal

-Clinical relapse in the 12 months prior to dosing

-New lesion formation (by comparison of screening MRI to a previous MRI of sufficient quality) in the 3 months prior to dosing

- One or more gadolinium-enhancing lesions on the screening scan

-Change in disease-modifying therapy in the 6 months prior to dosing

-Medical contraindication for 7-tesla MRI (including, but not limited to, any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects, or body piercings, that are not MRI-compatible or cannot be removed)

-Psychological contraindication for 7-tesla MRI (e.g., claustrophobia)

-Contraindication to gadolinium administration.

-Active neoplastic disease or any medical condition, other than MS, that requires concurrent immunosuppression or immunomodulation


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Daniel S. Reich, M.D.
National Institutes of Health Clinical Center (CC)



Joan M. Ohayon, C.R.N.P.
National Institutes of Health Clinical Center (CC)
BG 10 RM 5C442
10 CENTER DR
BETHESDA MD 20814
(301) 496-3825
eatonj@ninds.nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010
PRPL@cc.nih.gov

Clinical Trials Number:

NCT04025554

--Back to Top--